Showing results (1941-1950 of 2,065) with videos related to

Sort By:
Pageof 207
Annals of Family Medicine|January 25, 2024
Planning, operationalizing, and evaluating patient partners' engagement in primary care research: a logic modelMathieu Bisson, Catherine Hudon, Fred Burge, et al.
Clinical Colorectal Cancer|September 13, 2020
Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance StatusAvraham Travers, Azim Jalali, Stephen Begbie, et al.
Vaccine|April 25, 2016
Detection and characterization of viruses as field and vaccine strains in feedlot cattle with bovine respiratory diseaseR W Fulton, J M d'Offay, C Landis, et al.
Vaccine|August 15, 2006
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02AV Ann Stewart, Shannon M McGrath, Douglas S Walsh, et al.
Physical Therapy|February 2, 2021
Application of the Modified Incremental Step Test for Pulmonary RehabilitationAngela T Burge, Jose C Rodrigues, Michael J Abramson, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
Journal of Physical Activity & Health|December 11, 2020
The Impact of Pulmonary Rehabilitation on 24-Hour Movement Behavior in People With Chronic Obstructive Pulmonary Disease: New Insights From a Compositional PerspectiveAngela T Burge, Javier Palarea-Albaladejo, Anne E Holland, et al.
Cell Reports|April 13, 2016
Enhanced CLIP Uncovers IMP Protein-RNA Targets in Human Pluripotent Stem Cells Important for Cell Adhesion and SurvivalAnne E Conway, Eric L Van Nostrand, Gabriel A Pratt, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
Asia-Pacific Journal of Clinical Oncology|March 1, 2023
Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE studyTsai-Sheng Yang, Hong-Hwa Chen, Lin Bo-Wen, et al.
Pageof 207